Malabsorption syndrome refers to a group of disorders that impair the absorption of nutrients in the small intestine. Some of the key symptoms of malabsorption syndrome include chronic diarrhea, bloating, abdominal pain, weight loss and malnutrition.
The rising prevalence of intestinal disorders such as celiac disease, Crohn's disease and pancreatic insufficiency has significantly fueled the need for effective Malabsorption Syndrome Market treatment options.
The Global Malabsorption Syndrome Market is estimated to be valued at USD 3.42 Billion in 2024 and is expected to reach USD 5.41 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Key treatment approaches for malabsorption syndrome include nutritional supplements, vitamin injections, antidiarrheal medications and intestinal transplantation in severe cases. Nutritional supplements containing vitamins, minerals and other nutrients play a major role in preventing nutritional deficiencies caused by malabsorption.
Key players: Key players operating in the malabsorption syndrome treatment market are AbbVie, Allergan, Takeda Pharmaceutical, Pfizer, Janssen Pharmaceuticals, Novartis AG and others.
Key opportunities: Rising awareness about malabsorption syndrome and its treatment, growing digestive disorders patient pool and new product innovations are expected to create lucrative opportunities for market players in the coming years. Global expansion: Major companies are expanding their global presence through strategic acquisitions and partnerships. For instance, Takeda acquired Shire to strengthen its position in gastrointestinal and rare disease drug markets globally.
Market drivers and restrain
Market drivers: The increasing prevalence of celiac disease and inflammatory bowel disease are major drivers for the malabsorption syndrome treatment market. According to several studies, celiac disease affects approximately 1% of the global population.
Market restraints: High cost of specific treatment approaches such as intestinal transplantation and lack of effective treatment options for some causes of malabsorption limit the market potential to a certain extent.
Segment Analysis Malabsorption syndrome market can be segmented on the basis of syndrome type, treatment and end user. On the basis of syndrome type, the market has been divided into celiac disease, lactose intolerance, fructose malabsorption and others. Among these, celiac disease accounts for the largest share owing to genetic disposition of a section of population towards celiac disease. On the basis of treatment, the market has been segmented into medication, nutritional supplements and others. Medication is the dominating segment due to large patient pool requiring lifelong drug therapy for management of respective diseases. On the basis of end user, the market is divided into hospitals & clinics, diagnostic laboratories and others. Hospitals & clinics dominate the end user segment due to availability of advanced testing facilities and provision of inpatient and outpatient treatment therapy for malabsorption syndrome.
Global Analysis North America holds the largest share in malabsorption syndrome market due to genetic predisposition of celiac disease, lactose intolerance and growing awareness levels. Europe is the second largest regional market due to diagnostic awareness programs and patient support organizations. Asia Pacific is expected to be fastest growing regional market led by India and China due to growing healthcare expenditure, developing healthcare infrastructure and rising westernization of diets in these countries. Rising medical tourism and preference for vegetarian and low fiber diets also support growth.
Get this Report in Japanese Language: 吸収不良症候群市場
Get this Report in Korean Language: 흡수 장애 증후군 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Malabsorption Syndrome Market Trends and Share Analysis By Diagnosis (Tests, Imaging), Causative Diseases (Lactose Intolerance, Sprue, Cystic Fibrosis), Treatment (Gluten-Free Diet, Antidiarrheal Agents, Anti-Inflammatory Drugs), End User – Global Forecast Till 2023
Malabsorption Syndrome Market Size is expected to grow at a CAGR of 11.0% during the forecast period of 2017-2023.
Several factors such as rising cases of causative diseases, unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are propelling the growth of the global malabsorption syndrome market.
Children and adults with cystic fibrosis are at risk for low bone density, and related complications due to malabsorption of certain nutrients.
It is expected that the support provided by the government authorities for research & development and initiatives taken to improve the reimbursement policies in healthcare is likely to drive the European market.
According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure in Australia was USD 170.4 billion, which is recorded to be 3.6% higher than the expenditure of 2014-2015.